Pilot Trial of SDX/d-MPH Adult ADHD Examining Effects Throughout the Day
Psychopharmacology Bulletin · 2025
DOI: 10.64719/pb.4551 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Psychopharmacology Bulletin, 2025. Verfasst von Lenard A Adler und 5 weiteren Autor:innen. Beteiligte Einrichtung: Adler, MD, Departments of Psychiatry and Child and Adolescent Psychiatry, NYU Grossman School of Medicine, New York, NY, USA. Hauptthemen laut MEDLINE: Attention Deficit Disorder with Hyperactivity, Methylphenidate, Central Nervous System Stimulants, Dextroamphetamine. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objective
To examine the effects of Serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) on ADHD symptoms throughout the day in adults with DSM-5 ADHD.
Method
This was a 6-week pilot study that included 3 weeks of open label treatment with SDX/d-MPH (39.2/7.8 mg/day to 52.3/10.4 mg/day in clinical titration) after completion of a one-week screening period and a two-week observation period in seventeen adults with ADHD. Two subjects were discontinued from the trial, one for being placebo-responder and another for exhibiting blood pressure lability during the observation period. Of the remaining 15 subjects, one dropped out after one week on 39.2/7.8 mg/day, while all others completed the trial. All fifteen participants were included in the data analyses.
Results
There were substantial effects of SDX/d-MPH on all clinical measures, including investigator symptom scores (AISRS); self-report (ASRS) scores, time-sensitive ADHD (TASS) scores throughout the day, impairment (CGI) and executive function scores (BRIEF-A) and measures of medication smoothness (AMSES). SDX/d-MPH was generally well tolerated.
Conclusions
This pilot study is the first systematic treatment effect trial data for SDX/d-MPH in adults with DSM-5 ADHD. The data preliminarily supports the clinical efficacy of DSM/d-MPH in adult ADHD and its ability to ameliorate symptoms throughout the day.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Adler, MD, Departments of Psychiatry and Child and Adolescent Psychiatry, NYU Grossman School of Medicine, New York, NY, USA.
- Cho, MA, Departments of Psychiatry, NYU Grossman School of Medicine, New York, NY, USA.
- Leon, RN, Departments of Psychiatry, NYU Grossman School of Medicine, New York, NY, USA.
- Guschwan, MD, Departments of Psychiatry, NYU Grossman School of Medicine, New York, NY, USA.
- Massimi, BA, Departments of Psychiatry, NYU Grossman School of Medicine; Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- Anbarasan, MD, Departments of Psychiatry, NYU Grossman School of Medicine, New York, NY, USA.
Zitieren
APA
Adler, L. A., Cho, D., Leon, T., Guschwan, M., Massimi, C. A., & Anbarasan, D. (2025). Pilot Trial of SDX/d-MPH Adult ADHD Examining Effects Throughout the Day. Psychopharmacology Bulletin. https://doi.org/10.64719/pb.4551
Vancouver
Adler LA, Cho D, Leon T, Guschwan M, Massimi CA, Anbarasan D. Pilot Trial of SDX/d-MPH Adult ADHD Examining Effects Throughout the Day. Psychopharmacology Bulletin. 2025. doi:10.64719/pb.4551
BibTeX
@article{Adler2025,
author = {Adler, Lenard A and Cho, Dayeon and Leon, Terry and Guschwan, Mariane and Massimi, Caleb A and Anbarasan, Deepti},
title = {Pilot Trial of SDX/d-MPH Adult ADHD Examining Effects Throughout the Day},
journal = {Psychopharmacology Bulletin},
year = {2025},
doi = {10.64719/pb.4551}
}
EUVIMED